Wood D, Kosa K, Brown D, Ehrlich OG, Higgins PDR, Heller C. Preferences of adult patients with inflammatory bowel disease for attributes of clinical trials: evidence from a choice-based conjoint analysis. Crohns Colitis 360. 2020 Jan;2(1). doi: 10.1093/crocol/otz048
Christensen T, Riis AH, Hatch EE, Wise LA, Nielsen MG, Rothman KJ, Toft Sorensen H, Mikkelsen EM. Costs and efficiency of online and offline recruitment methods: a web-based cohort study. J Med Internet Res. 2017 Mar 1;19(3):e58. doi: 10.2196/jmir.6716
Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock S. Treatment interruption and regimen change in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. JHEOR. 2015 Apr;2(2):181-91.
Davis KL, Gutierrez B, Zyczynski T, Kaye JA. Real-world treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. JHEOR. 2015 Jan 6;2(2):119-30. doi: 10.36469/9894
Feltner D, Hill C, Lenderking W, Williams VS, Morlock R. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. J Psychiatr Res. 2009 Oct;43(15):1224-30.
Morlock RJ, Williams VS, Cappelleri JC, Harness J, Fehnel SE, Endicott J, Feltner D. Development and evaluation of the Daily Assessment of Symptoms – Anxiety (DAS-A) Scale to evaluate onset of symptom relief in patients with generalized anxiety disorder. J Psychiatr Res. 2008 Oct;42(12):1024-36.